Publication Name	World Journal of Clinical Pediatrics
Manuscript ID	125410
DOI	10.5409/wjcp.125410
Country	Egypt

Category	Pediatrics
Manuscript Type	Review
Article Title	Precision biologics in pediatric inflammatory bowel disease: Current evidence and emerging predictors
Manuscript Source	Invited Manuscript
All Author List	Mohammed Al-Beltagi, Nermin Kamal Saeed, Adel Salah Bediwy, Samir Hasan, Yasser Salah El-Sawaf and Reem Elbeltagi
Funding Agency and Grant Number
Corresponding Author	Mohammed Al-Beltagi, Consultant, Head, MD, PhD, Professor, Department of Pediatrics, Faculty of Medicine, Tanta University, 1 Hassan Radwan Street, Tanta 31511, Algharbia, Egypt. mbelrem@hotmail.com
Key Words	Inflammatory bowel diseases; Biological products; Therapeutic drug monitoring; Biomarkers; Precision medicine; Pediatrics; Vedolizumab; Ustekinumab
Core Tip	Pediatric inflammatory bowel disease shows marked heterogeneity in both disease biology and therapeutic response, making biologic selection challenging in routine practice. Although anti-tumor necrosis factor agents, vedolizumab, ustekinumab, and emerging interleukin-23 inhibitors have transformed outcomes, primary non-response and secondary loss of response remain common. This review summarizes current evidence on clinical, biochemical, pharmacokinetic, genetic, transcriptomic, immunologic, and microbiome-based predictors of biologic response in children with inflammatory bowel disease. It highlights therapeutic drug monitoring as the most established tool while emphasizing the limitations of single biomarkers. The review further discusses biologic-specific predictive signatures and the growing role of integrated multi-omics and artificial intelligence approaches. Collectively, these advances support a shift toward precision medicine, aiming to match the right biologic to the right patient at the right time.
Citation	Al-Beltagi M, Saeed NK, Bediwy AS, Hasan S, El-Sawaf YS, Elbeltagi R. Precision biologics in pediatric inflammatory bowel disease: Current evidence and emerging predictors. World J Clin Pediatr 2026; In press DOI: https://doi.org/10.5409/wjcp.125410
PDF	125410-in-press.pdf

Received	2026-07-07 09:22
Peer-Review Started	2026-07-07 09:23
First Decision by Editorial Office Director
Return for Revision	2026-08-22 06:19
Revised	2026-08-23 22:55
Publication Fee Transferred
Second Decision by Editor	2026-10-12 03:05
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-10-12 10:17
Articles in Press	2026-10-12 10:17
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2219-2808 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com